IL147421A0 - A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY - Google Patents

A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY

Info

Publication number
IL147421A0
IL147421A0 IL14742101A IL14742101A IL147421A0 IL 147421 A0 IL147421 A0 IL 147421A0 IL 14742101 A IL14742101 A IL 14742101A IL 14742101 A IL14742101 A IL 14742101A IL 147421 A0 IL147421 A0 IL 147421A0
Authority
IL
Israel
Prior art keywords
affcting
screening
signaling pathway
cancer drugs
ras signaling
Prior art date
Application number
IL14742101A
Original Assignee
Biogene Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogene Technologies Inc filed Critical Biogene Technologies Inc
Priority to IL14742101A priority Critical patent/IL147421A0/en
Publication of IL147421A0 publication Critical patent/IL147421A0/en
Priority to AU2002366989A priority patent/AU2002366989A1/en
Priority to PCT/IL2002/001056 priority patent/WO2003060161A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14742101A 2001-12-31 2001-12-31 A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY IL147421A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL14742101A IL147421A0 (en) 2001-12-31 2001-12-31 A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY
AU2002366989A AU2002366989A1 (en) 2001-12-31 2002-12-30 A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway
PCT/IL2002/001056 WO2003060161A2 (en) 2001-12-31 2002-12-30 A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14742101A IL147421A0 (en) 2001-12-31 2001-12-31 A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY

Publications (1)

Publication Number Publication Date
IL147421A0 true IL147421A0 (en) 2002-08-14

Family

ID=11075919

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14742101A IL147421A0 (en) 2001-12-31 2001-12-31 A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY

Country Status (3)

Country Link
AU (1) AU2002366989A1 (en)
IL (1) IL147421A0 (en)
WO (1) WO2003060161A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186024A1 (en) * 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605799A (en) * 1990-07-12 1997-02-25 University Of Utah Research Foundation Somatic mutations in neurofibromatosis type 1 gene in human tumors
US5227292A (en) * 1990-07-12 1993-07-13 University Of Utah Neurofibromatosis type 1 gene

Also Published As

Publication number Publication date
WO2003060161A2 (en) 2003-07-24
AU2002366989A1 (en) 2003-07-30
WO2003060161A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
GB0214013D0 (en) Pharmaceutical product
EP1478345A4 (en) Novel pharmaceutical dosage forms and method for producing same
EP1675555A4 (en) Pharmaceutical compositions for prevention of overdose or abuse
IL166286A0 (en) Multicomponent pharmaceutical dosage form
FR2811857B1 (en) SPALLATION DEVICE FOR THE PRODUCTION OF NEUTRONS
HK1146044A1 (en) Spirocyclic cyclohexane derivatives
EP1581188A4 (en) Pharmaceutical safety dosage forms
AU2003254177A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
PL1644257T3 (en) Method for the production of stopper capsules
ZA200509099B (en) Stabilized pharmaceutical product
PL377656A1 (en) Alpha2delta ligands for different pharmaceutical uses
PL375571A1 (en) Squeeze-bottle of liquid medicine
AU2003242988A1 (en) Process for the preparation of the anti-cancer drug imatinib and its analogues
AU2003256923A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
GB0117619D0 (en) Pharmaceutical dosage form
HK1069526A1 (en) Anti-influenza drugs
EP1585500A4 (en) Coated particles for sustained-release pharmaceutical administration
AU2003221699A8 (en) Pharmaceutical preparation for taste masking
IS7267A (en) Dihydrogen substituted dihydrofuranone and drugs containing these compounds
ITMI20020773A1 (en) DRUGS FOR THE TREATMENT OF ARTHRITIS
PL368532A1 (en) Method for the production of blister copper
ITMO20030177A0 (en) APPARATUS FOR THE PRODUCTION OF CAPSULES
IL147421A0 (en) A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY
GB2417685B (en) Method for augmenting the antitumor activity of anti-cancer agents
GB0215593D0 (en) New anticancer drugs